GRI Projected Dividend Yield
Com Par $0.0001co/GRI Bio Inc ( NASDAQ : GRI )GRI Bio, Inc. is a clinical-stage biopharmaceutical company. Co. is focused on discovering, developing, and commercializing therapies that target serious diseases associated with dysregulated immune responses leading to inflammatory, fibrotic, and autoimmune disorders. Its therapies are designed to target the activity of Natural Killer T (NKT) cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. Its lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as an oral therapeutic for the treatment of idiopathic pulmonary fibrosis (IPF). 20 YEAR PERFORMANCE RESULTS |
GRI Dividend History Detail GRI Dividend News GRI Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |